female and male adult patients with acute myeloid leukemia (AML) at first or second relapse after research hub

Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070)

This study is for adults with a type of blood cancer called AML that has come back or not responded to usual treatments. It's testing a new combination of medicines to see if it's safe and helps more people. It combines standard chemotherapy drugs with a newer drug called venetoclax.